SEC Form 4
------------

# FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287
Estimated average bu	urden
hours per response:	0.5

STATEMENT	OF CHANGE	S IN BENEFICIAL	. OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person <sup>*</sup> Hessekiel Jeffrey			2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>EXELIXIS</u> , <u>INC.</u> [ EXEL ]		tionship of Reporting P all applicable) Director	10% Owner		
(Last) (First) (Middle) C/O EXELIXIS, INC.			3. Date of Earliest Transaction (Month/Day/Year) 11/30/2023	X	Officer (give title below) EVP, General Cor	Other (specify below) unsel & Sec		
			4. If Amendment, Date of Original Filed (Month/Day/Year)	Line)	vidual or Joint/Group Filing (Check Applicable			
(Ctra at)				X	Form filed by One Re	eporting Person		
(Street) ALAMEDA	CA	94502			Form filed by More th Person	an One Reporting		
(City)	(State) (Zip)		Rule 10b5-1(c) Transaction Indication					
			X Check this box to indicate that a transaction was made pursua satisfy the affirmative defense conditions of Rule 10b5-1(c). S	ant to a contra ee Instructior	act, instruction or written ג 10.	plan that is intended to		

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code ( 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150. 4)
Common Stock	11/30/2023		<b>S</b> <sup>(1)</sup>		25,000	D	<b>\$22.01</b> <sup>(2)</sup>	583,345 <sup>(3)</sup>	D	
Common Stock	12/04/2023		<b>S</b> <sup>(1)</sup>		25,000	D	\$22.06 <sup>(4)</sup>	558,345(3)	D	
Common Stock								999 <sup>(5)</sup>	Ι	By 401(k)

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of Deriv Secu Acqu (A) o Dispo of (D (Instr	of Expiration		6. Date Exercisable and Expiration Date (Month/Day/Year)		d 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v			Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

#### Explanation of Responses:

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 23, 2022.

2. Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from \$22.00 to \$22.07. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4.

3. Includes 188,144 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

4. Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from \$22.00 to \$22.16. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4.

5. Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of November 29, 2023.

### **Remarks:**

/s/ Nina Ayer, Attorney in Fact 12/04/2023

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).